Table 4.
HE3286-0401 treatment effects in obese inflamed subgroups.
| Group | Effect | Value | Change | P | Testg | |
|---|---|---|---|---|---|---|
| HE3286 | Placebo | |||||
| Cohort 1 MCP > 40a |
ΔHOMA2 IRc | Day 84 mean | −0.1 | +0.4 | 0.02 | |
| ΔC-peptide | −0.03 | +0.1 | 0.04 | |||
| ΔHb | −0.25 | +0.06 | 0.02 | t-test | ||
| ΔHct | −0.06 | +0.09 | 0.02 | |||
| ΔRBC | −0.05 | +0.09 | 0.02 | |||
| ΔnHbA1c | Day 84 median | −0.34 | 0.03 | Wilcoxon | ||
| Day 84 median | 0.1 | — | ||||
| Day 84 numbers | 17⇓e 5⇑f | 9⇓ 16⇑ | 0.0008 | Fisher's Exact | ||
| Day 84 mean | −0.46 | −0.21 | — | |||
| Day 84 mean −2 outliersd |
−0.82 | −0.21 | 0.04 | t-test | ||
|
| ||||||
| Cohort 2 BMI > 31b |
ΔnHbA1c | Day 112 mean | −1.0 | 0.0007 | ||
| −0.3 | — | t-test | ||||
| −1.0 | −0.3 | 0.03 | ||||
| Day 112 median | −1.2 | 0.002 | Wilcoxon | |||
| −0.16 | — | |||||
| −1.2 | −0.16 | 0.02 | Mann Whitney | |||
aParticipants with baseline monocyte chemoattractant protein greater than the lowest tertile (40 pmol/L). bParticipants with baseline body mass index greater than the median (31 kg/m2). cΔ: change in; HOMA2 IR: homeostatic assessment model insulin resistance; Hb: hemoglobin; Hct: hematocrit, RBC: red blood cells; nHbA1c: normalized HbA1c (see Section 2 for details); dTwo outliers removed (outliers circled in Figure 4(c), Mahalanobis distance); eDecrease from zero change; fIncrease from zero change; gParametric means and t-test used for data with normally distributed data, Nonparametric medians, Wilcoxon, Mann Whitney, and Fisher's Exact test used for abnormally distributed data.